Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 17.955
Filter
1.
Adv Exp Med Biol ; 1451: 139-149, 2024.
Article in English | MEDLINE | ID: mdl-38801576

ABSTRACT

Variola virus is an anthroponotic agent that belongs to the orthopoxvirus family. It is an etiological agent of smallpox, an ancient disease that caused massive mortality of human populations. Twentieth century has witnessed the death of about 300 million people due to the unavailability of an effective vaccine. Early detection is the primary strategy to prevent an outbreak of smallpox. Variola virus forms the characteristic pus-filled pustules and centrifugal rash distribution in the infected patients while transmission occurs mainly through respiratory droplets during the early stage of infection. No antiviral drugs are approved for variola virus till date. Generation of first-generation vaccines helped in the eradication of smallpox which was declared by the World Health Organization.


Subject(s)
Smallpox , Variola virus , Humans , Variola virus/pathogenicity , Variola virus/genetics , Variola virus/physiology , Smallpox/virology , Smallpox/prevention & control , Smallpox/transmission , Animals , Smallpox Vaccine/immunology , Disease Outbreaks/prevention & control
2.
Adv Exp Med Biol ; 1451: 355-368, 2024.
Article in English | MEDLINE | ID: mdl-38801590

ABSTRACT

Monkeypox (mpox), a zoonotic disease caused by the monkeypox virus (MPXV), poses a significant public health threat with the potential for global dissemination beyond its endemic regions in Central and West Africa. This study explores the multifaceted aspects of monkeypox, covering its epidemiology, genomics, travel-related spread, mass gathering implications, and economic consequences. Epidemiologically, mpox exhibits distinct patterns, with variations in age and gender susceptibility. Severe cases can arise in immunocompromised individuals, underscoring the importance of understanding the factors contributing to its transmission. Genomic analysis of MPXV highlights its evolutionary relationship with the variola virus and vaccinia virus. Different MPXV clades exhibit varying levels of virulence and transmission potential, with Clade I associated with higher mortality rates. Moreover, the role of recombination in MPXV evolution remains a subject of interest, with implications for understanding its genetic diversity. Travel and mass gatherings play a pivotal role in the spread of monkeypox. The ease of international travel and increasing globalization have led to outbreaks beyond African borders. The economic ramifications of mpox outbreaks extend beyond public health. Direct treatment costs, productivity losses, and resource-intensive control efforts can strain healthcare systems and economies. While vaccination and mitigation strategies have proven effective, the cost-effectiveness of routine vaccination in non-endemic countries remains a subject of debate. This study emphasizes the role of travel, mass gatherings, and genomics in its spread and underscores the economic impacts on affected regions. Enhancing surveillance, vaccination strategies, and public health measures are essential in controlling this emerging infectious disease.


Subject(s)
Disease Outbreaks , Global Health , Monkeypox virus , Mpox (monkeypox) , Travel , Mpox (monkeypox)/epidemiology , Mpox (monkeypox)/virology , Mpox (monkeypox)/transmission , Humans , Disease Outbreaks/prevention & control , Monkeypox virus/genetics , Monkeypox virus/pathogenicity , Animals , Rare Diseases/epidemiology , Rare Diseases/genetics , Communicable Diseases, Emerging/epidemiology , Communicable Diseases, Emerging/transmission , Communicable Diseases, Emerging/virology , Communicable Diseases, Emerging/prevention & control , Public Health , Female , Zoonoses/epidemiology , Zoonoses/transmission , Zoonoses/virology , Male
3.
East Mediterr Health J ; 30(4): 292-299, 2024 May 14.
Article in English | MEDLINE | ID: mdl-38808405

ABSTRACT

Background: Although hepatitis B is vaccine-preventable, it remains a significant health problem. To the best of our knowledge, this is the first hepatitis B outbreak report from Türkiye. Aims: To investigate the cause of hepatitis B outbreak in a nursing home for the disabled and make recommendations for prevention. Methods: An outbreak of acute hepatitis B was declared in a nursing home for the disabled following the admission of 3 patients from the home in a hospital. Collaborative response was initiated with the Provincial Health Directorate through the Public Health Infectious Diseases Department. We began tracking the infection and monitoring active cases. Audits and controls were carried out to determine the source, establish protection and control measures, and prevent further transmission. Results: Six of the 65 nursing home residents were diagnosed with acute hepatitis B. Four of them had diabetes and their blood glucose levels were monitored for at least 12 months. Two of the patients had received dental treatment in the last 6 months. The frequency of both variables, which may be an indication of the transmission route, was statistically significantly greater in the acute hepatitis B group. All the patients who could be sequenced were identified as genotype D. While 3 patients recovered fully, 2 were diagnosed with chronic hepatitis B and one died due to fulminant hepatitis. Conclusion: Standard routine immunization should be implemented as a preventive measure for acute hepatitis B. Frequent supervision and training on hygiene practices and safety precautions should be conducted for care staff working in collective residential facilities.


Subject(s)
Disease Outbreaks , Hepatitis B , Nursing Homes , Humans , Disease Outbreaks/prevention & control , Male , Female , Hepatitis B/epidemiology , Hepatitis B/prevention & control , Aged , Middle Aged , Disabled Persons/statistics & numerical data , Adult , Acute Disease , Aged, 80 and over
4.
PLoS Negl Trop Dis ; 18(5): e0012173, 2024 May.
Article in English | MEDLINE | ID: mdl-38739650

ABSTRACT

BACKGROUND: Yellow fever (YF), a mosquito-borne viral hemorrhagic fever, is endemic in Uganda and causes frequent outbreaks. A total of 1.6 million people were vaccinated during emergency mass immunization campaigns in 2011 and 2016. This study explored local perceptions of YF emergency mass immunization among vulnerable groups to inform future vaccination campaigns. METHODOLOGY: In this qualitative study, we conducted 43 semi-structured interviews, 4 focus group discussions, and 10 expert interviews with 76 participants. Data were collected in six affected districts with emergency mass vaccination. We included vulnerable groups (people ≥ 65 years and pregnant women) who are typically excluded from YF vaccination except during mass immunization. Data analysis was conducted using grounded theory. Inductive coding was utilized, progressing through open, axial, and selective coding. PRINCIPAL FINDINGS: Participants relied on community sources for information about the YF mass vaccination. Information was disseminated door-to-door, in community spaces, during religious gatherings, and on the radio. However, most respondents had no knowledge of the vaccine, and it was unclear to them whether a booster dose was required. In addition, the simultaneous presidential election during the mass vaccination campaign led to suspicion and resistance to vaccination. The lack of reliable and trustworthy information and the politicization of vaccination campaigns reinforced mistrust of YF vaccines. CONCLUSIONS/SIGNIFICANCE: People in remote areas affected by YF outbreaks rely on community sources of information. We therefore recommend improving health education, communication, and engagement through respected and trusted community members. Vaccination campaigns can never be seen as detached from political systems and power relations.


Subject(s)
Health Knowledge, Attitudes, Practice , Mass Vaccination , Qualitative Research , Yellow Fever Vaccine , Yellow Fever , Humans , Uganda/epidemiology , Female , Yellow Fever/prevention & control , Yellow Fever/epidemiology , Male , Yellow Fever Vaccine/administration & dosage , Mass Vaccination/psychology , Aged , Middle Aged , Vulnerable Populations , Adult , Pregnancy , Disease Outbreaks/prevention & control , Focus Groups
5.
MMWR Morb Mortal Wkly Rep ; 73(19): 430-434, 2024 May 16.
Article in English | MEDLINE | ID: mdl-38753544

ABSTRACT

Measles is a highly infectious, vaccine-preventable disease that can cause severe illness, hospitalization, and death. A measles outbreak associated with a migrant shelter in Chicago occurred during February-April 2024, in which a total of 57 confirmed cases were identified, including 52 among shelter residents, three among staff members, and two among community members with a known link to the shelter. CDC simulated a measles outbreak among shelter residents using a dynamic disease model, updated in real time as additional cases were identified, to produce outbreak forecasts and assess the impact of public health interventions. As of April 8, the model forecasted a median final outbreak size of 58 cases (IQR = 56-60 cases); model fit and prediction range improved as more case data became available. Counterfactual analysis of different intervention scenarios demonstrated the importance of early deployment of public health interventions in Chicago, with a 69% chance of an outbreak of 100 or more cases had there been no mass vaccination or active case-finding compared with only a 1% chance when those interventions were deployed. This analysis highlights the value of using real-time, dynamic models to aid public health response, set expectations about outbreak size and duration, and quantify the impact of interventions. The model shows that prompt mass vaccination and active case-finding likely substantially reduced the chance of a large (100 or more cases) outbreak in Chicago.


Subject(s)
Disease Outbreaks , Measles , Humans , Disease Outbreaks/prevention & control , Chicago/epidemiology , Measles/epidemiology , Measles/prevention & control , Epidemiological Models , Public Health , Time Factors , Forecasting , Adolescent , Child , Child, Preschool , Mass Vaccination , Adult
6.
MMWR Morb Mortal Wkly Rep ; 73(19): 441-446, 2024 May 16.
Article in English | MEDLINE | ID: mdl-38753550

ABSTRACT

In 1988, poliomyelitis (polio) was targeted for eradication. Global efforts have led to the eradication of two of the three wild poliovirus (WPV) serotypes (types 2 and 3), with only WPV type 1 (WPV1) remaining endemic, and only in Afghanistan and Pakistan. This report describes global polio immunization, surveillance activities, and poliovirus epidemiology during January 2022-December 2023, using data current as of April 10, 2024. In 2023, Afghanistan and Pakistan identified 12 total WPV1 polio cases, compared with 22 in 2022. WPV1 transmission was detected through systematic testing for poliovirus in sewage samples (environmental surveillance) in 13 provinces in Afghanistan and Pakistan, compared with seven provinces in 2022. The number of polio cases caused by circulating vaccine-derived polioviruses (cVDPVs; circulating vaccine virus strains that have reverted to neurovirulence) decreased from 881 in 2022 to 524 in 2023; cVDPV outbreaks (defined as either a cVDPV case with evidence of circulation or at least two positive environmental surveillance isolates) occurred in 32 countries in 2023, including eight that did not experience a cVDPV outbreak in 2022. Despite reductions in paralytic polio cases from 2022, cVDPV cases and WPV1 cases (in countries with endemic transmission) were more geographically widespread in 2023. Renewed efforts to vaccinate persistently missed children in countries and territories where WPV1 transmission is endemic, strengthen routine immunization programs in countries at high risk for poliovirus transmission, and provide more effective cVDPV outbreak responses are necessary to further progress toward global polio eradication.


Subject(s)
Disease Eradication , Global Health , Immunization Programs , Poliomyelitis , Poliovirus , Population Surveillance , Poliomyelitis/epidemiology , Poliomyelitis/prevention & control , Humans , Global Health/statistics & numerical data , Poliovirus/isolation & purification , Disease Outbreaks/prevention & control , Poliovirus Vaccines/administration & dosage , Child, Preschool , Infant , Poliovirus Vaccine, Oral/administration & dosage
7.
MMWR Morb Mortal Wkly Rep ; 73(19): 435-440, 2024 May 16.
Article in English | MEDLINE | ID: mdl-38753567

ABSTRACT

Clade I monkeypox virus (MPXV), which can cause severe illness in more people than clade II MPXVs, is endemic in the Democratic Republic of the Congo (DRC), but the country has experienced an increase in suspected cases during 2023-2024. In light of the 2022 global outbreak of clade II mpox, the increase in suspected clade I cases in DRC raises concerns that the virus could spread to other countries and underscores the importance of coordinated, urgent global action to support DRC's efforts to contain the virus. To date, no cases of clade I mpox have been detected outside of countries in Central Africa where the virus is endemic. CDC and other partners are working to support DRC's response. In addition, CDC is enhancing U.S. preparedness by raising awareness, strengthening surveillance, expanding diagnostic testing capacity for clade I MPXV, ensuring appropriate specimen handling and waste management, emphasizing the importance of appropriate medical treatment, and communicating guidance on the recommended contact tracing, containment, behavior modification, and vaccination strategies.


Subject(s)
Disease Outbreaks , Mpox (monkeypox) , Democratic Republic of the Congo/epidemiology , Humans , United States/epidemiology , Mpox (monkeypox)/epidemiology , Disease Outbreaks/prevention & control , Centers for Disease Control and Prevention, U.S. , Monkeypox virus/isolation & purification
11.
Bull Math Biol ; 86(6): 73, 2024 May 13.
Article in English | MEDLINE | ID: mdl-38739351

ABSTRACT

Behavior change significantly influences the transmission of diseases during outbreaks. To incorporate spontaneous preventive measures, we propose a model that integrates behavior change with disease transmission. The model represents behavior change through an imitation process, wherein players exclusively adopt the behavior associated with higher payoff. We find that relying solely on spontaneous behavior change is insufficient for eradicating the disease. The dynamics of behavior change are contingent on the basic reproduction number R a corresponding to the scenario where all players adopt non-pharmaceutical interventions (NPIs). When R a < 1 , partial adherence to NPIs remains consistently feasible. We can ensure that the disease stays at a low level or maintains minor fluctuations around a lower value by increasing sensitivity to perceived infection. In cases where oscillations occur, a further reduction in the maximum prevalence of infection over a cycle can be achieved by increasing the rate of behavior change. When R a > 1 , almost all players consistently adopt NPIs if they are highly sensitive to perceived infection. Further consideration of saturated recovery leads to saddle-node homoclinic and Bogdanov-Takens bifurcations, emphasizing the adverse impact of limited medical resources on controlling the scale of infection. Finally, we parameterize our model with COVID-19 data and Tokyo subway ridership, enabling us to illustrate the disease spread co-evolving with behavior change dynamics. We further demonstrate that an increase in sensitivity to perceived infection can accelerate the peak time and reduce the peak size of infection prevalence in the initial wave.


Subject(s)
Basic Reproduction Number , COVID-19 , Disease Outbreaks , Mathematical Concepts , Models, Biological , Humans , Basic Reproduction Number/statistics & numerical data , COVID-19/transmission , COVID-19/epidemiology , COVID-19/prevention & control , Disease Outbreaks/prevention & control , SARS-CoV-2 , Computer Simulation , Health Behavior , Pandemics/prevention & control
13.
Euro Surveill ; 29(21)2024 May.
Article in English | MEDLINE | ID: mdl-38785093

ABSTRACT

BackgroundDuring the 2022 mpox outbreak in Europe, primarily affecting men who have sex with men, a limited number of cases among children and adolescents were identified. Paediatric cases from outbreaks in endemic countries have been associated with a higher likelihood of severe illness. Detailed clinical case descriptions and interventions in school settings before 2022 are limited.AimTo describe clinical characteristics of mpox cases among children (< 15 years) and adolescents (15-17 years) in the greater Paris area in France, and infection control measures in schools.MethodsWe describe all notified laboratory-confirmed and non-laboratory-confirmed cases among children and adolescents identified from May 2022 to July 2023, including demographic and clinical characterisation and infection control measures in school settings, i.e. contact tracing, contact vaccination, secondary attack rate and post-exposure vaccination uptake.ResultsNineteen cases were notified (13 children, 6 adolescents). Four adolescent cases reported sexual contact before symptom onset. Ten child cases were secondary cases of adult patients; three cases were cryptic, with vesicles on hands, arms and/or legs and one case additionally presented with genitoanal lesions. Five cases attended school during their infectious period, with 160 at-risk contacts identified, and one secondary case. Five at-risk contacts were vaccinated following exposure.ConclusionCases among children and adolescents are infrequent but require a careful approach to identify the source of infection and ensure infection control measures. We advocate a 'contact warning' strategy vs 'contact tracing' in order to prevent alarm and stigma. Low post-exposure vaccination rates are expected.


Subject(s)
Contact Tracing , Disease Outbreaks , Schools , Humans , Adolescent , Male , Child , Female , Disease Outbreaks/prevention & control , Paris/epidemiology , Vaccination/statistics & numerical data , Homosexuality, Male/statistics & numerical data , Follow-Up Studies , Meningococcal Infections/prevention & control , Meningococcal Infections/epidemiology
14.
Int J Public Health ; 69: 1606791, 2024.
Article in English | MEDLINE | ID: mdl-38721474

ABSTRACT

Objectives: To describe a suspected diphtheria outbreak in a Swiss asylum seeker reception centre, and to analyse its management response regarding testing and vaccination. Methods: We retrospectively analysed clinical, microbiology, and case management data of all asylum seekers tested for C. diphtheriae between 28th August and 31st December 2022 while residing at the centre. Results are reported descriptively. Results: Among 265 individuals tested, ten cases of cutaneous diphtheria, one simultaneous respiratory and cutaneous case, and nine respiratory carriers were identified. Mass throat screening, targeted throat testing and targeted wound testing yielded 4.8%, 4.3%, and 17.4% positive results, respectively. No respiratory carrier was identified among cutaneous cases undergoing a throat swab, and no symptomatic case was identified among individuals with unspecific throat symptoms. Rates of vaccination implementation of newly arriving asylum seekers before and after the outbreak were low (17.5% and 15.5%, respectively), as were rates of targeted vaccination among cases and close contacts. Conclusion: We provide evidence for transmission both prior to arrival and within the setting, suboptimal practices and timeliness of testing, and implementation gaps in vaccination.


Subject(s)
Diphtheria , Disease Outbreaks , Refugees , Humans , Switzerland , Refugees/statistics & numerical data , Diphtheria/prevention & control , Diphtheria/epidemiology , Disease Outbreaks/prevention & control , Retrospective Studies , Male , Female , Adult , Adolescent , Young Adult , Vaccination/statistics & numerical data , Corynebacterium diphtheriae , Middle Aged , Mass Screening
15.
J Health Popul Nutr ; 43(1): 62, 2024 May 10.
Article in English | MEDLINE | ID: mdl-38730508

ABSTRACT

INTRODUCTION: Seasonal influenza causes annual school breaks and student absenteeism in Hong Kong schools and kindergartens. This proposal aims to conduct a retrospective cohort study to evaluate the impact of a school-based influenza vaccination (SIV) programme on absenteeism and outbreaks at schools in Hong Kong. METHODS: The study will compare schools that implemented the SIV programme with schools that did not. The data will be sourced from school records, encompassing absenteeism records, outbreak reports, and vaccination rates. We will recruit 1000 students from 381 schools and kindergartens in 18 districts of Hong Kong starting June 2024. The primary outcome measures will include absenteeism rates due to influenza and school influenza outbreaks. Secondary outcomes will consist of vaccination coverage rates and the impact of the SIV programme on hospitalisations due to influenza-like illness. A t-test will be conducted to compare the outcomes between schools with and without the SIV programme. ETHICS AND DISSEMINATION: The school completed signing the participants' informed consent form before reporting the data to us. Our study has been approved by the Hospital Authority Hong Kong West Cluster IRB Committee (IRB No: UW 17-111) and was a subtopic of the research "The estimated age-group specific influenza vaccine coverage rates in Hong Kong and the impact of the school outreach vaccination program". TRIAL REGISTRATION: This study will be retrospectively registered.


Subject(s)
Absenteeism , Disease Outbreaks , Immunization Programs , Influenza Vaccines , Influenza, Human , School Health Services , Schools , Humans , Hong Kong/epidemiology , Retrospective Studies , Influenza, Human/prevention & control , Influenza, Human/epidemiology , Influenza Vaccines/administration & dosage , Influenza Vaccines/therapeutic use , Disease Outbreaks/prevention & control , Child , Female , Male , Vaccination/statistics & numerical data , Students/statistics & numerical data , Students/psychology , Program Evaluation , Adolescent , Child, Preschool , Cohort Studies
16.
J Med Microbiol ; 73(5)2024 May.
Article in English | MEDLINE | ID: mdl-38771623

ABSTRACT

The emergent fungal pathogen Candida auris is increasingly recognised as an important cause of healthcare-associated infections globally. It is highly transmissible, adaptable, and persistent, resulting in an organism with significant outbreak potential that risks devastating consequences. Progress in the ability to identify C. auris in clinical specimens is encouraging, but laboratory diagnostic capacity and surveillance systems are lacking in many countries. Intrinsic resistance to commonly used antifungals, combined with the ability to rapidly acquire resistance to therapy, substantially restricts treatment options and novel agents are desperately needed. Despite this, outbreaks can be interrupted, and mortality avoided or minimised, through the application of rigorous infection prevention and control measures with an increasing evidence base. This review provides an update on epidemiology, the impact of the COVID-19 pandemic, risk factors, identification and typing, resistance profiles, treatment, detection of colonisation, and infection prevention and control measures for C. auris. This review has informed a planned 2024 update to the United Kingdom Health Security Agency (UKHSA) guidance on the laboratory investigation, management, and infection prevention and control of Candida auris. A multidisciplinary response is needed to control C. auris transmission in a healthcare setting and should emphasise outbreak preparedness and response, rapid contact tracing and isolation or cohorting of patients and staff, strict hand hygiene and other infection prevention and control measures, dedicated or single-use equipment, appropriate disinfection, and effective communication concerning patient transfers and discharge.


Subject(s)
Antifungal Agents , COVID-19 , Candida auris , Candidiasis , Infection Control , Humans , Candidiasis/prevention & control , Candidiasis/epidemiology , Candidiasis/drug therapy , Candidiasis/microbiology , Infection Control/methods , Candida auris/drug effects , COVID-19/prevention & control , COVID-19/epidemiology , Antifungal Agents/therapeutic use , Antifungal Agents/pharmacology , England/epidemiology , Cross Infection/prevention & control , Cross Infection/epidemiology , Cross Infection/microbiology , SARS-CoV-2 , Drug Resistance, Fungal , Candida/drug effects , Candida/classification , Candida/isolation & purification , Disease Outbreaks/prevention & control
17.
PLoS One ; 19(5): e0303062, 2024.
Article in English | MEDLINE | ID: mdl-38758971

ABSTRACT

Correctional centres (termed here 'prisons') are at high risk of COVID-19 and have featured major outbreaks worldwide. Inevitable close contacts, frequent inmate movements, and a disproportionate burden of co-morbidities mean these environments need to be prioritised in any public health response to respiratory pathogens such as COVID-19. We developed an individual-based SARS-CoV-2 transmission model for the prison system in New South Wales, Australia - incorporating all 33 correctional centres, 13,458 inmates, 578 healthcare and 6,909 custodial staff. Potential COVID-19 disease outbreaks were assessed under various mitigation strategies, including quarantine on entry, isolation of cases, rapid antigen testing of staff, as well as immunisation.Without control measures, the model projected a peak of 472 new infections daily by day 35 across the prison system, with all inmates infected by day 120. The most effective individual mitigation strategies were high immunisation coverage and prompt lockdown of centres with infected inmates which reduced outbreak size by 62-73%. Other than immunisation, the combination of quarantine of inmates at entry, isolation of proven or suspected cases, and widespread use of personal protective equipment by staff and inmates was the most effective strategy. High immunisation coverage mitigates the spread of COVID-19 within and between correctional settings but is insufficient alone. Maintaining quarantine and isolation, along with high immunisation levels, will allow correctional systems to function with a low risk of outbreaks. These results have informed public health policy for respiratory pathogens in Australian correctional systems.


Subject(s)
COVID-19 , Disease Outbreaks , Models, Theoretical , Prisons , Quarantine , SARS-CoV-2 , COVID-19/epidemiology , COVID-19/prevention & control , COVID-19/transmission , Humans , Prisons/statistics & numerical data , Disease Outbreaks/prevention & control , New South Wales/epidemiology , SARS-CoV-2/isolation & purification , Personal Protective Equipment
18.
Emerg Microbes Infect ; 13(1): 2356143, 2024 Dec.
Article in English | MEDLINE | ID: mdl-38767202

ABSTRACT

ABSTRACTImproved sanitation, increased access to health care, and advances in preventive and clinical medicine have reduced the mortality and morbidity rates of several infectious diseases. However, recent outbreaks of several emerging infectious diseases (EIDs) have caused substantial mortality and morbidity, and the frequency of these outbreaks is likely to increase due to pathogen, environmental, and population effects driven by climate change. Extreme or persistent changes in temperature, precipitation, humidity, and air pollution associated with climate change can, for example, expand the size of EID reservoirs, increase host-pathogen and cross-species host contacts to promote transmission or spillover events, and degrade the overall health of susceptible host populations leading to new EID outbreaks. It is therefore vital to establish global strategies to track and model potential responses of candidate EIDs to project their future behaviour and guide research efforts on early detection and diagnosis technologies and vaccine development efforts for these targets. Multi-disciplinary collaborations are demanding to develop effective inter-continental surveillance and modelling platforms that employ artificial intelligence to mitigate climate change effects on EID outbreaks. In this review, we discuss how climate change has increased the risk of EIDs and describe novel approaches to improve surveillance of emerging pathogens that pose the risk for EID outbreaks, new and existing measures that could be used to contain or reduce the risk of future EID outbreaks, and new methods to improve EID tracking during further outbreaks to limit disease transmission.


Subject(s)
Climate Change , Communicable Diseases, Emerging , Humans , Communicable Diseases, Emerging/epidemiology , Communicable Diseases, Emerging/prevention & control , Communicable Diseases, Emerging/transmission , Animals , Disease Outbreaks/prevention & control
19.
Rev Med Virol ; 34(3): e2541, 2024 May.
Article in English | MEDLINE | ID: mdl-38743385

ABSTRACT

As the mankind counters the ongoing COVID-19 pandemic by the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), it simultaneously witnesses the emergence of mpox virus (MPXV) that signals at global spread and could potentially lead to another pandemic. Although MPXV has existed for more than 50 years now with most of the human cases being reported from the endemic West and Central African regions, the disease is recently being reported in non-endemic regions too that affect more than 50 countries. Controlling the spread of MPXV is important due to its potential danger of a global spread, causing severe morbidity and mortality. The article highlights the transmission dynamics, zoonosis potential, complication and mitigation strategies for MPXV infection, and concludes with suggested 'one health' approach for better management, control and prevention. Bibliometric analyses of the data extend the understanding and provide leads on the research trends, the global spread, and the need to revamp the critical research and healthcare interventions. Globally published mpox-related literature does not align well with endemic areas/regions of occurrence which should ideally have been the scenario. Such demographic and geographic gaps between the location of the research work and the endemic epicentres of the disease need to be bridged for greater and effective translation of the research outputs to pubic healthcare systems, it is suggested.


Subject(s)
Bibliometrics , Humans , Disease Outbreaks/prevention & control , Animals , Mpox (monkeypox)/epidemiology , Mpox (monkeypox)/transmission , Mpox (monkeypox)/prevention & control , Mpox (monkeypox)/virology , COVID-19/transmission , COVID-19/epidemiology , COVID-19/prevention & control , COVID-19/virology , SARS-CoV-2 , Zoonoses/epidemiology , Zoonoses/virology , Zoonoses/transmission , Zoonoses/prevention & control , Pandemics/prevention & control
20.
PLoS One ; 19(4): e0299844, 2024.
Article in English | MEDLINE | ID: mdl-38626045

ABSTRACT

BACKGROUND: The Australian Government implemented a national vaccination campaign against COVID-19 beginning February 22, 2021. The roll-out was criticised for being delayed relative to many high-income countries, but high levels of vaccination coverage were belatedly achieved. The large-scale Omicron outbreak in January 2022 resulted in a massive number of cases and deaths, although mortality would have been far higher if not for vigorous efforts to rapidly vaccinate the entire population. The impact of the vaccination coverage was assessed over this extended period. METHODS: We considered NSW, as the Australian jurisdiction with the highest quality data for our purposes and which still reflected the national experience. Weekly death rates were derived among individuals aged 50+ with respect to vaccine status between August 8, 2021 and July 9, 2022. We evaluated deaths averted by the vaccination campaign by modelling alternative counterfactual scenarios based on a simple data-driven modelling methodology presented by Jia et al. (2023). FINDINGS: Unvaccinated individuals had a 7.7-fold greater mortality rate than those who were fully vaccinated among people aged 50+, which rose to 11.2-fold in those who had received a booster dose. If NSW had fully vaccinated its ~2.9 million 50+ residents earlier (by July 28, 2021), only 440 of the total 3,495 observed 50+ deaths would have been averted. Up to July 9, 2022, the booster campaign prevented 1,860 deaths. In the absence of a vaccination campaign, ~21,250 COVID-19 50+ deaths (conservative estimate) could have been expected in NSW i.e., some 6 times the actual total. We also find the methodology of Jia et al. (2023) can sometimes significantly underestimate that actual number. INTERPRETATION: The Australian vaccination campaign was successful in reducing mortality over 2022, relative to alternative hypothetical vaccination scenarios. The success was attributable to the Australian public's high levels of engagement with vaccination in the face of new SARS-COV-2 variants, and because high levels of vaccination coverage (full and booster) were achieved in the period shortly before the major Omicron outbreak of 2022.


Subject(s)
COVID-19 , Humans , Australia/epidemiology , COVID-19/epidemiology , COVID-19/prevention & control , Cluster Analysis , Disease Outbreaks/prevention & control , Immunization Programs , Vaccination
SELECTION OF CITATIONS
SEARCH DETAIL
...